Bevacizumab and Retinal Vascular Occlusions - Full Text View

Home Search Study Topics Glossary

Bevacizumab and Retinal Vascular Occlusions

This study is currently recruiting participants.

Verified by Asociación para Evitar la Ceguera en México, June 2006

Sponsored by:	Asociación para Evitar la Ceguera en México
Information provided by:	Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:	NCT00347711

Purpose

To evaluate the effects of Intravitreal Bevacizumab in macular edema in retinal vascular occlusion.

Condition	Intervention	Phase
Edema Macular Vascular Occlusion	Drug: Intravitreal injection	Phase III

MedlinePlus related topics: Edema

Drug Information available for: Bevacizumab

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Uncontrolled, Single Group Assignment

Eligibility

Ages Eligible for Study:	40 Years to 90 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Vascular occlusion and edema macular diagnosticated by fluorescein angiography and coherent optic tomography

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00347711

Locations

Mexico, D.F. Mexico
Asociacion para Evitar la Ceguera en Mexico	Recruiting
Mexico, D.F. Mexico, Mexico, 04030
Contact: Griselda Alvarez, Fellow 5255 10841400 ext 1171 retinamex@yahoo.com.

Sponsors and Collaborators

Asociación para Evitar la Ceguera en México

Investigators

Principal Investigator:

Griselda Alvarez, Fellow

APEC

More Information

Study ID Numbers:	APEC-0020
Study First Received:	June 30, 2006
Last Updated:	July 3, 2006
ClinicalTrials.gov Identifier:	NCT00347711
Health Authority:	Mexico: Secretaria de Salud

Study placed in the following topic categories:

Edema
Bevacizumab

ClinicalTrials.gov processed this record on January 14, 2009